BACKGROUND: The prevalence of the metabolic syndrome (MetSyn) approaches 50% in postmenopausal women. This study examines the efficacy of lifestyle modification for the treatment of MetSyn and its associated risk for cardiovascular disease and diabetes in this population. METHODS: This prospective controlled study examines the effects of a 6-month weight loss and low-intensity exercise program (WL+LEX) on body composition (dual-energy X-ray absorptiometry and abdominal computed tomography scans), fasting glucose and lipid levels, cytokines, and blood pressure in postmenopausal women with and without MetSyn. RESULTS:WL+LEXreduced body weight (MetSyn: -5% vs non-MetSyn: -7%) and fat mass (-11% vs -15%) and increased VO(2max) (+2% vs +3%) in both MetSyn (N = 35) and non-MetSyn (N = 41) groups. Constituents of MetSyn decreased comparably in both groups. Fifteen (45%) MetSyn participants responded (R) by converting to non-MetSyn, 18 remained MetSyn (NR), and 2 had missing data. Reduction in fat mass (-15% vs -8%, p = .02) was greater in R than NR, but there were no between-group differences in changes in VO(2max), cytokines, or other variables. The decrease in the number of MetSyn criteria was greater in R than in NR (-27 vs -13, p < .0001) due to decreases in blood pressure (p < .01), glucose (p = .02), and with a trend for triglyceride (p = .07). Reductions in fat mass best predicted resolution of MetSyn (p = .04). CONCLUSIONS: Women who lose more fat are more likely to lower blood pressure, glucose, and triglyceride levels to resolve MetSyn. Thus, a WL+LEX program effectively treats postmenopausal women with MetSyn.
RCT Entities:
BACKGROUND: The prevalence of the metabolic syndrome (MetSyn) approaches 50% in postmenopausal women. This study examines the efficacy of lifestyle modification for the treatment of MetSyn and its associated risk for cardiovascular disease and diabetes in this population. METHODS: This prospective controlled study examines the effects of a 6-month weight loss and low-intensity exercise program (WL+LEX) on body composition (dual-energy X-ray absorptiometry and abdominal computed tomography scans), fasting glucose and lipid levels, cytokines, and blood pressure in postmenopausal women with and without MetSyn. RESULTS: WL+LEX reduced body weight (MetSyn: -5% vs non-MetSyn: -7%) and fat mass (-11% vs -15%) and increased VO(2max) (+2% vs +3%) in both MetSyn (N = 35) and non-MetSyn (N = 41) groups. Constituents of MetSyn decreased comparably in both groups. Fifteen (45%) MetSyn participants responded (R) by converting to non-MetSyn, 18 remained MetSyn (NR), and 2 had missing data. Reduction in fat mass (-15% vs -8%, p = .02) was greater in R than NR, but there were no between-group differences in changes in VO(2max), cytokines, or other variables. The decrease in the number of MetSyn criteria was greater in R than in NR (-27 vs -13, p < .0001) due to decreases in blood pressure (p < .01), glucose (p = .02), and with a trend for triglyceride (p = .07). Reductions in fat mass best predicted resolution of MetSyn (p = .04). CONCLUSIONS:Women who lose more fat are more likely to lower blood pressure, glucose, and triglyceride levels to resolve MetSyn. Thus, a WL+LEX program effectively treats postmenopausal women with MetSyn.
Authors: Eija Ruotsalainen; Urpu Salmenniemi; Ilkka Vauhkonen; Jussi Pihlajamäki; Kari Punnonen; Sakari Kainulainen; Markku Laakso Journal: Diabetes Care Date: 2006-12 Impact factor: 19.112
Authors: Edward P Weiss; Susan B Racette; Dennis T Villareal; Luigi Fontana; Karen Steger-May; Kenneth B Schechtman; Samuel Klein; Ali A Ehsani; John O Holloszy Journal: J Appl Physiol (1985) Date: 2006-11-09
Authors: Tongjian You; Barbara J Nicklas; Jingzhong Ding; Brenda W J H Penninx; Bret H Goodpaster; Douglas C Bauer; Frances A Tylavsky; Tamara B Harris; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2008-04 Impact factor: 6.053
Authors: Evadnie Rampersaud; Braxton D Mitchell; Toni I Pollin; Mao Fu; Haiqing Shen; Jeffery R O'Connell; Julie L Ducharme; Scott Hines; Paul Sack; Rosalie Naglieri; Alan R Shuldiner; Soren Snitker Journal: Arch Intern Med Date: 2008-09-08
Authors: Brenda W J H Penninx; Barbara J Nicklas; Anne B Newman; Tamara B Harris; Bret H Goodpaster; Suzanne Satterfield; Nathalie de Rekeneire; Kristine Yaffe; Marco Pahor; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2009-01-20 Impact factor: 6.053
Authors: Steven J Prior; Andrew P Goldberg; Heidi K Ortmeyer; Eva R Chin; Dapeng Chen; Jacob B Blumenthal; Alice S Ryan Journal: Diabetes Date: 2015-06-11 Impact factor: 9.461
Authors: Edward P Weiss; Dominic N Reeds; Uthayashanker R Ezekiel; Stewart G Albert; Dennis T Villareal Journal: Endocrine Date: 2016-09-07 Impact factor: 3.633
Authors: Xuewen Wang; Fang-Chi Hsu; Scott Isom; Michael P Walkup; Stephen B Kritchevsky; Bret H Goodpaster; Timothy S Church; Marco Pahor; Randall S Stafford; Barbara J Nicklas Journal: J Gerontol A Biol Sci Med Sci Date: 2011-10-24 Impact factor: 6.053
Authors: Steven K Malin; Nicole Niemi; Thomas P J Solomon; Jacob M Haus; Karen R Kelly; Julianne Filion; Michael Rocco; Sangeeta R Kashyap; Hope Barkoukis; John P Kirwan Journal: Ann Nutr Metab Date: 2012 Impact factor: 3.374
Authors: Michael Miller; John D Sorkin; Laura Mastella; Aimee Sutherland; Jeffrey Rhyne; Patrick Donnelly; Kathy Simpson; Andrew P Goldberg Journal: J Clin Lipidol Date: 2016-05-06 Impact factor: 4.766
Authors: Rian Q Landers-Ramos; Kelsey J Corrigan; Lisa M Guth; Christine N Altom; Espen E Spangenburg; Steven J Prior; James M Hagberg Journal: Appl Physiol Nutr Metab Date: 2016-03-28 Impact factor: 2.665